Literature DB >> 16112298

Adjuvant trastuzumab for HER2-positive breast cancer.

James Spicer, Mark Harries, Paul Ellis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16112298     DOI： 10.1016/S0140-6736(05)67134-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 2.  Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

Authors:  Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Epigenetic regulation of ZEB1-RAB25/ESRP1 axis plays a critical role in phenylbutyrate treatment-resistant breast cancer.

Authors:  Mariko Kikuchi; Keishi Yamashita; Mina Waraya; Naoko Minatani; Hideki Ushiku; Ken Kojo; Akira Ema; Yoshimasa Kosaka; Hiroshi Katoh; Norihiko Sengoku; Takumo Enomoto; Hirokazu Tanino; Masakazu Sawanobori; Masahiko Watanabe
Journal:  Oncotarget       Date:  2016-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.